These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25790234)

  • 1. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
    Weng Y; Chabot JR; Bernardo B; Yan Q; Zhu Y; Brenner MB; Vage C; Logan A; Calle R; Talukdar S
    PLoS One; 2015; 10(3):e0119104. PubMed ID: 25790234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
    Dong JQ; Rossulek M; Somayaji VR; Baltrukonis D; Liang Y; Hudson K; Hernandez-Illas M; Calle RA
    Br J Clin Pharmacol; 2015 Nov; 80(5):1051-63. PubMed ID: 25940675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
    Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
    Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.
    Thompson WC; Zhou Y; Talukdar S; Musante CJ
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):411-25. PubMed ID: 27405817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
    Weng Y; Ishino T; Sievers A; Talukdar S; Chabot JR; Tam A; Duan W; Kerns K; Sousa E; He T; Logan A; Lee D; Li D; Zhou Y; Bernardo B; Joyce A; Kavosi M; O'Hara DM; Clark T; Guo J; Giragossian C; Stahl M; Calle RA; Kriz R; Somers W; Lin L
    Sci Rep; 2018 Mar; 8(1):4241. PubMed ID: 29523796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
    Véniant MM; Komorowski R; Chen P; Stanislaus S; Winters K; Hager T; Zhou L; Wada R; Hecht R; Xu J
    Endocrinology; 2012 Sep; 153(9):4192-203. PubMed ID: 22798348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
    Kim AM; Somayaji VR; Dong JQ; Rolph TP; Weng Y; Chabot JR; Gropp KE; Talukdar S; Calle RA
    Diabetes Obes Metab; 2017 Dec; 19(12):1762-1772. PubMed ID: 28573777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.
    Müller TD; Sullivan LM; Habegger K; Yi CX; Kabra D; Grant E; Ottaway N; Krishna R; Holland J; Hembree J; Perez-Tilve D; Pfluger PT; DeGuzman MJ; Siladi ME; Kraynov VS; Axelrod DW; DiMarchi R; Pinkstaff JK; Tschöp MH
    J Pept Sci; 2012 Jun; 18(6):383-93. PubMed ID: 22565812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
    Talukdar S; Zhou Y; Li D; Rossulek M; Dong J; Somayaji V; Weng Y; Clark R; Lanba A; Owen BM; Brenner MB; Trimmer JK; Gropp KE; Chabot JR; Erion DM; Rolph TP; Goodwin B; Calle RA
    Cell Metab; 2016 Mar; 23(3):427-40. PubMed ID: 26959184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance.
    Bernardo B; Lu M; Bandyopadhyay G; Li P; Zhou Y; Huang J; Levin N; Tomas EM; Calle RA; Erion DM; Rolph TP; Brenner M; Talukdar S
    Sci Rep; 2015 Jul; 5():11382. PubMed ID: 26153793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
    Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
    Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
    Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
    Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
    Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.
    Albarazanji K; Jennis M; Cavanaugh CR; Lang W; Singh B; Lanter JC; Lenhard JM; Hornby PJ
    Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G653-G667. PubMed ID: 30920846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
    Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
    Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss.
    Badman MK; Kennedy AR; Adams AC; Pissios P; Maratos-Flier E
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1197-204. PubMed ID: 19738035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.
    Huang J; Ishino T; Chen G; Rolzin P; Osothprarop TF; Retting K; Li L; Jin P; Matin MJ; Huyghe B; Talukdar S; Bradshaw CW; Palanki M; Violand BN; Woodnutt G; Lappe RW; Ogilvie K; Levin N
    J Pharmacol Exp Ther; 2013 Aug; 346(2):270-80. PubMed ID: 23720456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity.
    Yin J; Bao L; Tian H; Wang Q; Gao X; Yao W
    Br J Pharmacol; 2016 Jul; 173(14):2208-23. PubMed ID: 27339749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of β-Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity.
    Samms RJ; Cheng CC; Kharitonenkov A; Gimeno RE; Adams AC
    Endocrinology; 2016 Apr; 157(4):1467-80. PubMed ID: 26901091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys.
    Andersen B; Straarup EM; Heppner KM; Takahashi DL; Raffaele V; Dissen GA; Lewandowski K; Bödvarsdottir TB; Raun K; Grove KL; Kievit P
    Int J Obes (Lond); 2018 Jun; 42(6):1151-1160. PubMed ID: 29892039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.